Preclinical delayed toxicity studies of BCMA CAR T-cell injection in B-NDG mice with multiple myeloma
PurposeBased on the efficacy data from the previous study of B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell injection, we further examined the delayed toxicity for 8 weeks after a single dose of BCMA CAR T-cell injection to observe possible toxic reactions.MethodsB-NDG mice...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-11-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1435934/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846169365622292480 |
|---|---|
| author | Jianmin Guo Jianmin Guo Jianmin Guo Qiqi Wu Qiqi Wu Hongjian Li Hongjian Li Chun Liang Jinlong Dai Jinlong Dai Shuren Zhang Shuren Zhang Cailing Dai Cailing Dai Jishuai Zhang Jishuai Zhang Yuying Wen Yuying Wen Wei Yang Wei Yang Wei Yang |
| author_facet | Jianmin Guo Jianmin Guo Jianmin Guo Qiqi Wu Qiqi Wu Hongjian Li Hongjian Li Chun Liang Jinlong Dai Jinlong Dai Shuren Zhang Shuren Zhang Cailing Dai Cailing Dai Jishuai Zhang Jishuai Zhang Yuying Wen Yuying Wen Wei Yang Wei Yang Wei Yang |
| author_sort | Jianmin Guo |
| collection | DOAJ |
| description | PurposeBased on the efficacy data from the previous study of B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell injection, we further examined the delayed toxicity for 8 weeks after a single dose of BCMA CAR T-cell injection to observe possible toxic reactions.MethodsB-NDG mice transplanted with multiple myeloma (MM) cells were given a single dose of BCMA CAR T-cell injection at two dosages or human normal T cells and then subjected to examinations including clinical signs, weight and food intake measurements, haematology, blood biochemical analysis, cytokine assay, T-lymphocyte subpopulation quantification and histopathology on days 28 and 56 after dosing. In addition, quantitative polymerase chain reaction (qPCR) was used to quantify DNA fragments in different tissues to assess the tissue distribution of CAR and provide a basis for its preclinical safety evaluation and clinical dosing.ResultsIn the delayed toxicity study, no mortality or significant toxic effects such as reductions in food intake, body weight, relevant biochemical parameters and target organ weights were observed in the BCMA CAR T-cell-treated groups. Compared to the model group, restorative changes in clinical signs and clinicopathology indicating therapeutic effects were seen in the BCMA CAR T-cell-treated groups. Human-derived cytokines interleukin-2 (IL-2), IL-4, IL-6, IL-12, IL-10, tumor necrosis factor α (TNF-α), and interferon-γ (IFN-γ) could be detected in all cancer cell–bearing mice by cytokine level measurement. IFN-γ levels showed a geometric increase due to the graft versus host disease (GVHD) response induced in the mice, while the levels of the other cytokines did not show significant changes. Histopathological examination indicated that the BCMA CAR T-cell treatment groups showed mixed cellular infiltration of human-derived T cells, cancer cells, and inflammatory cells in several target organs including the liver, spleen, lung, and kidney, and some of them showed mild tissue damage, but the number of the animals and the severity of damage were significantly less than those of the T-cell control group as well as the model group. The results of the tissue distribution study showed that BCMA CAR T cells were mainly concentrated in the kidney, lung, bone marrow and the related immune organs/tissues, and the distribution of BCMA CAR T cells was highly consistent with that of MM cells, suggesting that BCMA CAR T cells could follow the cancer cells during metastatic targeting of the tissues.ConclusionsThe present study demonstrated a low toxicity of BCMA CAR T-cell injection, with manageable side effects and good anticancer activity and without observable adverse effects. This study provides data to support future clinical studies of BCMA CAR T-cell injection for MM. |
| format | Article |
| id | doaj-art-c94470036fd449c2b731f4acb07932c3 |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-c94470036fd449c2b731f4acb07932c32024-11-13T04:36:49ZengFrontiers Media S.A.Frontiers in Immunology1664-32242024-11-011510.3389/fimmu.2024.14359341435934Preclinical delayed toxicity studies of BCMA CAR T-cell injection in B-NDG mice with multiple myelomaJianmin Guo0Jianmin Guo1Jianmin Guo2Qiqi Wu3Qiqi Wu4Hongjian Li5Hongjian Li6Chun Liang7Jinlong Dai8Jinlong Dai9Shuren Zhang10Shuren Zhang11Cailing Dai12Cailing Dai13Jishuai Zhang14Jishuai Zhang15Yuying Wen16Yuying Wen17Wei Yang18Wei Yang19Wei Yang20Division of Life Science and State Key Lab of Molecular Neuroscience, Hong Kong University of Science and Technology, Hong Kong, Hong Kong SAR, ChinaGuangzhou Bay Area Institute of Biomedicine, Guangdong Lewwin Pharmaceutical Research Institute Co.,Ltd., Guangdong Provincial Key Laboratory of Drug Non-Clinical Evaluation and Research, Guangdong Engineering Research Center for Innovative Drug Evaluation and Research, Guangzhou, ChinaGuangdong Engineering Research Center for Cellular and Genetic Therapy Innovative Drugs, Shenzhen, ChinaGuangzhou Bay Area Institute of Biomedicine, Guangdong Lewwin Pharmaceutical Research Institute Co.,Ltd., Guangdong Provincial Key Laboratory of Drug Non-Clinical Evaluation and Research, Guangdong Engineering Research Center for Innovative Drug Evaluation and Research, Guangzhou, ChinaCollege of Pharmacy, Guilin Medical University, Guilin, ChinaGuangdong Engineering Research Center for Cellular and Genetic Therapy Innovative Drugs, Shenzhen, ChinaShenzhen Pregene Biopharma Company Ltd., Research and Development (R&D) Department, Shenzhen, ChinaDivision of Life Science and State Key Lab of Molecular Neuroscience, Hong Kong University of Science and Technology, Hong Kong, Hong Kong SAR, ChinaGuangzhou Bay Area Institute of Biomedicine, Guangdong Lewwin Pharmaceutical Research Institute Co.,Ltd., Guangdong Provincial Key Laboratory of Drug Non-Clinical Evaluation and Research, Guangdong Engineering Research Center for Innovative Drug Evaluation and Research, Guangzhou, ChinaGuangdong Engineering Research Center for Cellular and Genetic Therapy Innovative Drugs, Shenzhen, ChinaGuangzhou Bay Area Institute of Biomedicine, Guangdong Lewwin Pharmaceutical Research Institute Co.,Ltd., Guangdong Provincial Key Laboratory of Drug Non-Clinical Evaluation and Research, Guangdong Engineering Research Center for Innovative Drug Evaluation and Research, Guangzhou, ChinaGuangdong Engineering Research Center for Cellular and Genetic Therapy Innovative Drugs, Shenzhen, ChinaGuangzhou Bay Area Institute of Biomedicine, Guangdong Lewwin Pharmaceutical Research Institute Co.,Ltd., Guangdong Provincial Key Laboratory of Drug Non-Clinical Evaluation and Research, Guangdong Engineering Research Center for Innovative Drug Evaluation and Research, Guangzhou, ChinaGuangdong Engineering Research Center for Cellular and Genetic Therapy Innovative Drugs, Shenzhen, ChinaGuangzhou Bay Area Institute of Biomedicine, Guangdong Lewwin Pharmaceutical Research Institute Co.,Ltd., Guangdong Provincial Key Laboratory of Drug Non-Clinical Evaluation and Research, Guangdong Engineering Research Center for Innovative Drug Evaluation and Research, Guangzhou, ChinaGuangdong Engineering Research Center for Cellular and Genetic Therapy Innovative Drugs, Shenzhen, ChinaGuangzhou Bay Area Institute of Biomedicine, Guangdong Lewwin Pharmaceutical Research Institute Co.,Ltd., Guangdong Provincial Key Laboratory of Drug Non-Clinical Evaluation and Research, Guangdong Engineering Research Center for Innovative Drug Evaluation and Research, Guangzhou, ChinaGuangdong Engineering Research Center for Cellular and Genetic Therapy Innovative Drugs, Shenzhen, ChinaDivision of Life Science and State Key Lab of Molecular Neuroscience, Hong Kong University of Science and Technology, Hong Kong, Hong Kong SAR, ChinaGuangzhou Bay Area Institute of Biomedicine, Guangdong Lewwin Pharmaceutical Research Institute Co.,Ltd., Guangdong Provincial Key Laboratory of Drug Non-Clinical Evaluation and Research, Guangdong Engineering Research Center for Innovative Drug Evaluation and Research, Guangzhou, ChinaGuangdong Engineering Research Center for Cellular and Genetic Therapy Innovative Drugs, Shenzhen, ChinaPurposeBased on the efficacy data from the previous study of B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell injection, we further examined the delayed toxicity for 8 weeks after a single dose of BCMA CAR T-cell injection to observe possible toxic reactions.MethodsB-NDG mice transplanted with multiple myeloma (MM) cells were given a single dose of BCMA CAR T-cell injection at two dosages or human normal T cells and then subjected to examinations including clinical signs, weight and food intake measurements, haematology, blood biochemical analysis, cytokine assay, T-lymphocyte subpopulation quantification and histopathology on days 28 and 56 after dosing. In addition, quantitative polymerase chain reaction (qPCR) was used to quantify DNA fragments in different tissues to assess the tissue distribution of CAR and provide a basis for its preclinical safety evaluation and clinical dosing.ResultsIn the delayed toxicity study, no mortality or significant toxic effects such as reductions in food intake, body weight, relevant biochemical parameters and target organ weights were observed in the BCMA CAR T-cell-treated groups. Compared to the model group, restorative changes in clinical signs and clinicopathology indicating therapeutic effects were seen in the BCMA CAR T-cell-treated groups. Human-derived cytokines interleukin-2 (IL-2), IL-4, IL-6, IL-12, IL-10, tumor necrosis factor α (TNF-α), and interferon-γ (IFN-γ) could be detected in all cancer cell–bearing mice by cytokine level measurement. IFN-γ levels showed a geometric increase due to the graft versus host disease (GVHD) response induced in the mice, while the levels of the other cytokines did not show significant changes. Histopathological examination indicated that the BCMA CAR T-cell treatment groups showed mixed cellular infiltration of human-derived T cells, cancer cells, and inflammatory cells in several target organs including the liver, spleen, lung, and kidney, and some of them showed mild tissue damage, but the number of the animals and the severity of damage were significantly less than those of the T-cell control group as well as the model group. The results of the tissue distribution study showed that BCMA CAR T cells were mainly concentrated in the kidney, lung, bone marrow and the related immune organs/tissues, and the distribution of BCMA CAR T cells was highly consistent with that of MM cells, suggesting that BCMA CAR T cells could follow the cancer cells during metastatic targeting of the tissues.ConclusionsThe present study demonstrated a low toxicity of BCMA CAR T-cell injection, with manageable side effects and good anticancer activity and without observable adverse effects. This study provides data to support future clinical studies of BCMA CAR T-cell injection for MM.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1435934/fullmultiple myelomachimeric antigen receptor T cellsimmunotherapyB-cell maturation antigencytokinesdelayed toxicity |
| spellingShingle | Jianmin Guo Jianmin Guo Jianmin Guo Qiqi Wu Qiqi Wu Hongjian Li Hongjian Li Chun Liang Jinlong Dai Jinlong Dai Shuren Zhang Shuren Zhang Cailing Dai Cailing Dai Jishuai Zhang Jishuai Zhang Yuying Wen Yuying Wen Wei Yang Wei Yang Wei Yang Preclinical delayed toxicity studies of BCMA CAR T-cell injection in B-NDG mice with multiple myeloma Frontiers in Immunology multiple myeloma chimeric antigen receptor T cells immunotherapy B-cell maturation antigen cytokines delayed toxicity |
| title | Preclinical delayed toxicity studies of BCMA CAR T-cell injection in B-NDG mice with multiple myeloma |
| title_full | Preclinical delayed toxicity studies of BCMA CAR T-cell injection in B-NDG mice with multiple myeloma |
| title_fullStr | Preclinical delayed toxicity studies of BCMA CAR T-cell injection in B-NDG mice with multiple myeloma |
| title_full_unstemmed | Preclinical delayed toxicity studies of BCMA CAR T-cell injection in B-NDG mice with multiple myeloma |
| title_short | Preclinical delayed toxicity studies of BCMA CAR T-cell injection in B-NDG mice with multiple myeloma |
| title_sort | preclinical delayed toxicity studies of bcma car t cell injection in b ndg mice with multiple myeloma |
| topic | multiple myeloma chimeric antigen receptor T cells immunotherapy B-cell maturation antigen cytokines delayed toxicity |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1435934/full |
| work_keys_str_mv | AT jianminguo preclinicaldelayedtoxicitystudiesofbcmacartcellinjectioninbndgmicewithmultiplemyeloma AT jianminguo preclinicaldelayedtoxicitystudiesofbcmacartcellinjectioninbndgmicewithmultiplemyeloma AT jianminguo preclinicaldelayedtoxicitystudiesofbcmacartcellinjectioninbndgmicewithmultiplemyeloma AT qiqiwu preclinicaldelayedtoxicitystudiesofbcmacartcellinjectioninbndgmicewithmultiplemyeloma AT qiqiwu preclinicaldelayedtoxicitystudiesofbcmacartcellinjectioninbndgmicewithmultiplemyeloma AT hongjianli preclinicaldelayedtoxicitystudiesofbcmacartcellinjectioninbndgmicewithmultiplemyeloma AT hongjianli preclinicaldelayedtoxicitystudiesofbcmacartcellinjectioninbndgmicewithmultiplemyeloma AT chunliang preclinicaldelayedtoxicitystudiesofbcmacartcellinjectioninbndgmicewithmultiplemyeloma AT jinlongdai preclinicaldelayedtoxicitystudiesofbcmacartcellinjectioninbndgmicewithmultiplemyeloma AT jinlongdai preclinicaldelayedtoxicitystudiesofbcmacartcellinjectioninbndgmicewithmultiplemyeloma AT shurenzhang preclinicaldelayedtoxicitystudiesofbcmacartcellinjectioninbndgmicewithmultiplemyeloma AT shurenzhang preclinicaldelayedtoxicitystudiesofbcmacartcellinjectioninbndgmicewithmultiplemyeloma AT cailingdai preclinicaldelayedtoxicitystudiesofbcmacartcellinjectioninbndgmicewithmultiplemyeloma AT cailingdai preclinicaldelayedtoxicitystudiesofbcmacartcellinjectioninbndgmicewithmultiplemyeloma AT jishuaizhang preclinicaldelayedtoxicitystudiesofbcmacartcellinjectioninbndgmicewithmultiplemyeloma AT jishuaizhang preclinicaldelayedtoxicitystudiesofbcmacartcellinjectioninbndgmicewithmultiplemyeloma AT yuyingwen preclinicaldelayedtoxicitystudiesofbcmacartcellinjectioninbndgmicewithmultiplemyeloma AT yuyingwen preclinicaldelayedtoxicitystudiesofbcmacartcellinjectioninbndgmicewithmultiplemyeloma AT weiyang preclinicaldelayedtoxicitystudiesofbcmacartcellinjectioninbndgmicewithmultiplemyeloma AT weiyang preclinicaldelayedtoxicitystudiesofbcmacartcellinjectioninbndgmicewithmultiplemyeloma AT weiyang preclinicaldelayedtoxicitystudiesofbcmacartcellinjectioninbndgmicewithmultiplemyeloma |